Blog
How to get insurance approval for a rare-disease or orphan drug
A playbook for a rare diagnosis: confirm the labeled use, build the evidence packet, request approval, appeal, use external review and open parallel paths.
A rare-disease drug is often the only treatment for a condition, costs a great deal, and arrives with a plan reviewer who has seen few or no cases. That combination is why approvals for these drugs tend to go slowly and sometimes begin with a denial. A denial is not the end. Plans are expected to decide against written criteria, you can see those criteria, and most of what wins an approval is documentation: a clear diagnosis, the evidence behind the drug, the specialist's reasoning and a record of what has already been tried.
This playbook is written for a patient or for the parent or caregiver of a patient. It lays out the steps in order, who does each one, and what to ask. It does not give medical advice. Treatment choices belong to the patient and the specialist, and what a particular plan will do belongs to that plan's documents and decision.
Step 1: Confirm what the drug is approved to treat
Start with the drug's FDA-approved labeling, which lists the conditions, ages and doses for which the FDA found it safe and effective. Ask the specialist for the exact approved indication and whether your diagnosis matches it, including any restriction in the label, for example a specific genetic variant, an age range, a disease stage or a requirement that other treatments be tried first.
Three terms are easy to confuse:
- Orphan designation. Under the Orphan Drug Act, the FDA can designate a drug for a rare disease, one affecting fewer than 200,000 people in the United States, which gives the maker certain incentives. A designation is not an approval. A drug with the designation may still be in testing.
- FDA approval. The drug has been reviewed and approved for stated uses. Plans generally start from the approved uses.
- Approval for a different use. If the drug is approved but not for your diagnosis, the request is for off-label use, which plans evaluate differently. The post my doctor prescribed a drug off-label: will insurance pay for it? covers that route.
If the drug is not FDA-approved at all, insurance coverage is unlikely, and the specialist may talk with you about clinical trials or expanded access programs. The FDA has a process, often called expanded access or compassionate use, under which a doctor can request an unapproved drug for a patient with a serious condition who has no comparable alternatives. It requires the maker's agreement and is separate from insurance.
Step 2: Ask the plan for its rules before the request
Do not wait for the denial to learn the criteria. Ask the plan, or look in its drug list and medical policies:
- Is the drug covered, and under which benefit, pharmacy or medical? (See why is my injection billed to my medical benefit and not my pharmacy benefit? for why that matters.)
- Does it require prior authorization? If so, ask for the written criteria and the form.
- Does the plan require the drug to come from a particular specialty pharmacy or be given at a particular type of site?
- Does the plan limit the diagnosis, the specialist's type, the age or the dose?
- How long does a decision take, and is there an expedited option?
Ask for the plan's clinical policy for the drug by name. Many plans publish these. Write down the date, the person and what you were told. The prior authorization and claim tracker gives you a place to keep it.
Step 3: Build the evidence packet with the specialist
The approval request will be read by a pharmacist or physician reviewer who may not know the condition. Make it easy for them to say yes. A strong packet usually contains:
- Confirmed diagnosis. The diagnosis and the date, with the tests that support it: genetic testing, biopsy, imaging, lab values or the specific diagnostic criteria for the condition. Rare diseases often require specific testing, and a plan may refuse without it.
- Why this drug. The specialist's statement of why the drug is indicated for you, and why alternatives are not suitable.
- Treatment history. Every prior treatment tried, with dates, doses, outcomes and reasons for stopping: lack of benefit, side effects, contraindications. If a step-therapy rule applies, this section matters most.
- Current status. Baseline measures of the disease: symptoms, function, scores or test results that the plan can later compare against.
- The label and the evidence. The FDA label, the pivotal trial publication or summary, and any treatment guidelines or consensus statements from the relevant professional society.
- Treatment goals and monitoring. What improvement the specialist expects and how it will be measured. Plans often renew approvals only when there is evidence the drug is working.
- Prescriber details. The specialist's name, specialty and any center of excellence involvement, since some policies require a specific type of prescriber.
Ask for a copy of the whole packet. You will need it if there is an appeal, and the claim denial appeal letter builder draws on the same material.
Step 4: Submit the request, and ask for urgency when it applies
The prescriber's office usually submits the request. Before it goes in, ask:
- Does the form match the plan's current criteria? (Plans update forms.)
- Is everything attached? A missing lab result or note is a common reason for delay or denial.
- Is the request marked for expedited review, if waiting could seriously harm the patient? Expedited review depends on the prescriber's statement that a delay could jeopardize life, health or ability to regain function. Do not use the label lightly, but do not leave it off when it is true.
- What is the reference number, and when will you hear back?
Write down the date. Call after a few business days if you have heard nothing. The guide how prior authorization works and what to do when it is denied explains the typical stages and what time limits generally apply.
Step 5: If the plan asks for more, or approves with limits
Plans sometimes request more records, or approve the drug with conditions: a smaller quantity, a shorter period, a specific pharmacy, or renewal criteria. Read the approval letter closely and record the end date. For a rare-disease drug that is meant to be continued, a lapse in approval can mean a gap in treatment, so put the renewal date on a calendar six to eight weeks before it.
If the plan approves only part of the request, such as a lower dose than prescribed, ask the prescriber whether to appeal the difference.
Step 6: If the plan denies, read the reason and appeal
The denial notice should state the reason, the criteria used and how to appeal. Read the reason carefully. Rare-disease denials commonly fall into a few groups:
- Not medically necessary, meaning the plan says the criteria were not met. The fix is more or clearer evidence.
- Experimental or investigational, which the plan may say if there is little published evidence. The fix is the label, the trial data and professional guidelines, and a statement from the specialist.
- Step therapy not completed, where the fix is either to document why the earlier steps are inappropriate or were tried, or to request an exception. The guide step therapy explained: "fail first" rules and how to get an exception covers exceptions.
- Missing information or the wrong form, which can be cured by resubmitting.
- Out-of-network or non-preferred site or pharmacy, which may need a network exception.
The internal appeal
You, or the prescriber on your behalf, can file an internal appeal with the plan. For most plans, you have at least 180 days from the denial notice to file, though the notice states the exact date. File as early as you can, since the plan's answer takes time and some plans have faster tracks for urgent cases. The appeal should respond to the reason in the denial, not just repeat the first request. The guide how to appeal a denied health insurance claim, step by step gives the full steps and the how long does a drug coverage appeal take, step by step? post lays out the time limits for a drug appeal.
Add to the packet: a stronger letter from the specialist that answers the denial reason point by point, new records and any published evidence the first request lacked. If more than one specialist has treated you, a second letter helps.
Peer-to-peer review
Ask the prescriber to request a peer-to-peer review, a phone call between the prescriber and a plan physician reviewer. Rare-disease cases benefit from a conversation with someone who can hear the clinical reasoning. Prepare a short summary of three or four points, and have the records at hand. The post peer-to-peer review mistakes that cost patients the approval describes common missteps.
Step 7: External review
If the internal appeal fails, most plans give you the right to an independent external review, in which a reviewer who does not work for the plan decides. For insured plans, the process is run under state or federal rules and is generally available for denials based on medical necessity and for experimental or investigational denials. The decision is binding on the plan if it is in your favor. The notice describes how to ask and the deadline, which is commonly four months from the final internal denial for many plans. Check the notice, because rules differ by plan type. The guide external review explained: when an independent reviewer decides describes how it works.
Rare-disease cases often do well in external review when the packet shows a clear diagnosis, the label, the evidence and the specialist's reasoning, because the reviewer is typically a physician with experience in the field. That is not a promise of an outcome in your case.
If your plan is a self-funded employer plan, federal rules govern the appeal and external review process, and the employer's benefits team and the plan's documents are the starting points. The state insurance department handles complaints about insured plans.
Step 8: Open parallel paths while you wait
Do not wait for the appeal to start these. Each takes time.
- Manufacturer support. Many drug makers run support programs that include a case manager, benefit investigation, and in some cases a free supply or a short-term bridge while coverage is pending. The prescriber's office or the drug's website can show what exists. Eligibility rules differ.
- Copay assistance, with limits. For people with commercial insurance, a maker's copay program may reduce the cost share once the drug is approved. Programs like this generally cannot be used by people in Medicare or Medicaid. Ask whether your plan has an accumulator, as described in How to find out if my plan has a copay accumulator before I enroll.
- Independent foundations. Charitable funds sometimes help with cost sharing for specific conditions. Their funds open and close, so ask the specialist's office and the patient organization.
- State and public programs. Some states have programs for specific conditions or for high drug costs, and Medicaid or a state program may offer routes your private plan does not. A social worker at the specialist's clinic or hospital is often the best person to ask.
- Patient organizations. Many rare conditions have a patient advocacy group that knows which plans cover the drug, which letters worked and which specialists to see. The National Organization for Rare Disorders and the NIH's Genetic and Rare Diseases Information Center are places to start, and a group dedicated to your condition may be more specific.
- Clinical trials and expanded access. The specialist can say whether a trial or an expanded access request fits.
Step 9: After approval
Keep the packet current. Many approvals are time-limited and require renewal evidence. Track measures the plan asked for, such as scores, lab values or functional changes, and give them to the prescriber before the renewal date. If you change plans, for example at open enrollment or a job change, ask the new plan about a continuity-of-care or transition supply before the first fill, and send the old approval letter and the packet to the new plan's prior authorization team.
A short checklist
- Label checked, and the diagnosis matches the approved use.
- Plan criteria and form obtained in writing.
- Evidence packet complete: diagnosis, history, specialist letter, label, studies, baseline.
- Request submitted, reference number and date logged, urgency marked if it applies.
- Denial read for its stated reason, deadline noted.
- Internal appeal and peer-to-peer requested with a point-by-point letter.
- External review filed on time if the internal appeal fails.
- Manufacturer, foundation, state and patient-organization routes opened in parallel.
- Renewal date on the calendar.
Key takeaways
- Approval turns on documentation: a confirmed diagnosis, the drug's labeled use, the specialist's reasoning, what has been tried, and a baseline the plan can measure against.
- Get the plan's written criteria for the drug before you submit, and build the packet to answer each one.
- A denial gives you rights: an internal appeal, a peer-to-peer call and, in most cases, an independent external review. The notice states the deadlines.
- Open manufacturer, foundation, state and patient-organization routes while the request is pending, since each takes time.
- Treatment decisions belong to you and your specialist. For questions about your plan's rules, ask the plan, and for complaints about an insured plan, ask the state insurance department.